LyncBio Therapeutics Secures Pre-A+ Financing to Advance Global First-in-human IBD iADC into the Clinic and Accelerate Bispecific Oncology ADC Platform

Jun 24 , 2026

SHANGHAI, China — Jun. 24, 2026 — LyncBio Therapeutics (Shanghai) Co., Ltd. ("LyncBio"), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs), today announced the successful completion of a nearly 100 million RMB Pre-A+ financing round. Coming just five months after its previous funding, this round highlights LyncBio's rapid operational execution, marked by the Phase I clinical trial initiation of its lead autoimmune asset and robust validat

LyncBio Therapeutics, an Emerging Innovator in ADC Development, Closes Pre-A Financing Round

Dec 25 , 2025

LyncBio Therapeutics (Shanghai) Co., Ltd. ("LyncBio"), a fast-growing biotech company in China dedicated to developing innovative Antibody-Drug Conjugates (ADCs) for both autoimmune disorders and cancer, recently announced the successful completion of the strategic Pre-A financing round.

Official Announcement on the Simultaneous Launch of LyncBio Digital Platforms

Nov 21 , 2025

The official website and WeChat Official Account of LyncBio have been officially launched and put into operation simultaneously.